Patents by Inventor Tama Evron

Tama Evron has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • COMPOUNDS AND METHODS FOR THE TREATMENT OF NEUROLOGICAL DISORDERS
    Publication number: 20180161310
    Abstract: Compounds that inhibit synaptic hyperexcitability, pharmaceutical compositions of these compounds, and methods of using the compounds and pharmaceutical compositions thereof to treat diseases and/or disorders such as epilepsy, neuropathic pain, spinal cord injury spasticity, morphine-induced hyperalgesia, schizophrenia, and autism spectrum disorders are disclosed.
    Type: Application
    Filed: December 7, 2017
    Publication date: June 14, 2018
    Inventors: Randall T. Peterson, David Kokel, Tama Evron, Andrea Velenich
  • Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
    Publication number: 20090281165
    Abstract: The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
    Type: Application
    Filed: October 7, 2008
    Publication date: November 12, 2009
    Inventors: Hermona Soreq, Shlomo Saidman, Jackiline Saidman, Tama Evron
  • Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
    Patent number: 7456154
    Abstract: The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
    Type: Grant
    Filed: February 1, 2006
    Date of Patent: November 25, 2008
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Hermona Soreq, Jackilynne Seidman, legal representative, Tama Evron, Shlomo Seidman
  • Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
    Publication number: 20060178333
    Abstract: The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
    Type: Application
    Filed: February 1, 2006
    Publication date: August 10, 2006
    Inventors: Hermona Soreq, Shlomo Saidman, Jackiline Saidman, Tama Evron
  • Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
    Patent number: 7074915
    Abstract: The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
    Type: Grant
    Filed: March 27, 2003
    Date of Patent: July 11, 2006
    Assignee: Yissum Research Development Company of the Hebrew University of Jerusalem
    Inventors: Hermona Soreq, Jackiline Saidman, legal representative, Tama Evron, Shlomo Saidman, deceased
  • Antisense oligonucleotide against human acetylcholinesterase (AChE) and uses thereof
    Publication number: 20030216344
    Abstract: The invention relates to an antisense oligonucleotide targeted to the coding region of the human acetylcholinesterase (AChE), which selectively suppresses the AChE-R isoform of the enzyme. The antisense oligonucleotide is intended for use in the treatment and/or prevention of neuromuscular disorders, preferably myasthenia gravis. In addition, it can penetrate the blood-brain barrier (BBB) and destroy AChE-R within central nervous system neurons, while also serving as a carrier to transport molecules across the BBB.
    Type: Application
    Filed: March 27, 2003
    Publication date: November 20, 2003
    Inventors: Hermona Soreq, Shlomo Saidman, Jackiline Saidman, Tama Evron